X4 Pharmaceuticals Lands $150M Debt Facility With K2 HealthVentures
X4 Pharmaceuticals secured up to $150 million in senior debt financing, retiring its prior loan and extending its runway for clinical and commercial operations.
X4 Pharmaceuticals has closed a senior debt facility worth up to $150 million with K2 HealthVentures, the company announced, replacing an existing loan arrangement and broadening its financial flexibility as it advances a late-stage clinical program.
The new facility retires X4's prior loan in full, eliminating a near-term liability and positioning the biotech to direct capital toward both corporate operations and commercial-stage activities. Access to fresh capital at this scale is a meaningful development for a specialty pharmaceutical company navigating the cost-intensive final stretch of clinical development.
Read more Swvl H1 2026 Revenue Jumps 59% to $16.2M on GCC Surge →
X4 said it expects to complete enrollment in its Phase 3 4WARD trial by the end of 2026, with topline efficacy data anticipated in the first half of 2028. The 4WARD trial represents the company's pivotal effort to generate the evidence needed for potential regulatory submission, making the funding timeline directly relevant to that milestone.
The K2 HealthVentures partnership signals continued institutional confidence in X4's pipeline. Specialty lenders in the life sciences sector typically conduct rigorous diligence before extending facilities of this size to clinical-stage companies, and the deal structure suggests K2 views the 4WARD readout as a credible near-term catalyst.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
